Ayrmid 
Welcome,         Profile    Billing    Logout  
 3 Products   5 Diseases  3 Products   7 Trials   262 News 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Aphexda (motixafortide) / BioLineRx, Ayrmid
GENESIS, NCT03246529 / 2018-001715-79: A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

Active, not recruiting
3
180
Europe, US
BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF
BioLineRx, Ltd.
Multiple Myeloma
12/20
09/29
NCT06514508: Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients

Not yet recruiting
3
60
RoW
Motixafortide+G-CSF, BL-8040+G-CSF, Placebo+G-CSF
Guangzhou Gloria Biosciences Co., Ltd.
Multiple Myeloma
08/26
12/26
NCT02639559: Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

Completed
2
50
US
BL-8040, Leukapheresis, Hematopoietic cell transplant
Washington University School of Medicine, BioLineRx, Ltd.
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease, Hodgkins Disease, Hodgkin's Disease, Multiple Myeloma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
04/18
04/23
NCT02907099: Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

Checkmark Data from trial in combination with BL-8040 in pancreatic cancer
Nov 2019 - Nov 2019: Data from trial in combination with BL-8040 in pancreatic cancer
Completed
2
20
US
CXCR4 Antagonist BL-8040, BKT140, BL-8040, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pharmacological Study
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
10/23
10/23
Chemo4METPANC, NCT04543071: Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Recruiting
2
10
US
Motixafortide, BL-8040, Cemiplimab, REGN2810, Gemcitabine, Gemzar, Nab paclitaxel, Abraxane
Gulam Manji, Regeneron Pharmaceuticals, BioLine Rx
Pancreatic Cancer, Adenocarcinoma of the Pancreas, Adenocarcinoma
06/28
08/28
MORPHEUS-EC, NCT03281369 / 2016-004529-17: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Active, not recruiting
1/2
410
Europe, US, RoW
5-Fluorouracil (5-FU), Leucovorin, Folinic acid, Oxaliplatin, Atezolizumab, Tecentriq, Cobimetinib, Cotellic, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Cisplatin, Tiragolumab, RO7092284
Hoffmann-La Roche, Halozyme Therapeutics, BioLineRx, Ltd.
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
09/25
09/25
MORPHEUS-PDAC, NCT03193190 / 2016-004126-42: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Hourglass Feb 2024 - Jun 2024 : Results from MORPHEUS-PDAC trial in 1L mPDAC
Checkmark In combination with BL-8040 for pancreatic ductal adenocarcinoma
Dec 2019 - Dec 2019: In combination with BL-8040 for pancreatic ductal adenocarcinoma
Completed
1/2
341
Europe, Japan, US, RoW
Nab-Paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Fluorouracil, Atezolizumab, Cobimetinib, PEGPH20, BL-8040, Selicrelumab, Bevacizumab, RO6874281, AB928, Tiragolumab, Tocilizumab
Hoffmann-La Roche
Pancreatic Adenocarcinoma
02/25
02/25
NCT05618301: Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

Active, not recruiting
1
10
US
Motixafortide, BL-8040, Natalizumab, Tysabri, Leukapheresis
Washington University School of Medicine, BioLineRx, Ltd., Biogen
Sickle Cell Disease
06/25
06/25
NCT06547112: A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization

Recruiting
1
20
US
Motixafortide, BL-8040, G-CSF
Washington University School of Medicine, BioLineRx, Ltd., Arvrmid Pharma
Multiple Myeloma
01/26
01/26
NCT06442761: SCD Stem Cell Mobilization and Apheresis Using Motixafortide

Recruiting
1
15
US
Motixafortide, APHEXDA™
St. Jude Children's Research Hospital, BioLineRx, Ltd.
Sickle Cell Disease
01/26
07/26
Omisirge (omidubicel) / Ayrmid
GC P#05.01.020, NCT02730299 / 2016-000704-28: Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

Completed
3
125
Europe, US, RoW
NiCord® (omidubicel), Cord Blood Unit
Gamida Cell ltd
Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Lymphoma, Acute Leukemia
04/21
02/25
NCT04260698: Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

Completed
3
36
US
omidubicel, NiCord
Gamida Cell ltd
Hematological Malignancies
05/25
05/25
NCT03173937: Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

Recruiting
1/2
37
US
Omidubicel (former CordIn), Miltenyi CliniMACS(R) CD34 Reagent System
National Heart, Lung, and Blood Institute (NHLBI)
Severe Aplastic Anemia, Hypo-Plastic MDS, Myelodysplastic Syndrome (MDS)
04/27
03/32
NCT06731504: HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT

Not yet recruiting
1
10
NA
Abatacept
Duke University
Hematologic Malignancy
12/27
07/28
NCT02039557 / 2015-004813-26: Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients

Completed
N/A
33
Europe, US, RoW
NiCord®/CordIn™ (omidubicel)
Gamida Cell ltd
Patients Transplanted With NiCord/CordIn (Omidubicel)
06/23
06/23
GDA-201 / Ayrmid
NCT05296525: Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL

Terminated
1/2
13
US
GDA-201, Nicotinamide (NAM) NK
Gamida Cell ltd
Non-Hodgkin Lymphoma
04/24
04/24
GDA-301 / Ayrmid
No trials found
GDA-401 / Ayrmid
No trials found
GDA-501 / Ayrmid
No trials found
GDA-601 / Ayrmid
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Aphexda (motixafortide) / BioLineRx, Ayrmid
GENESIS, NCT03246529 / 2018-001715-79: A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

Active, not recruiting
3
180
Europe, US
BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF
BioLineRx, Ltd.
Multiple Myeloma
12/20
09/29
NCT06514508: Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients

Not yet recruiting
3
60
RoW
Motixafortide+G-CSF, BL-8040+G-CSF, Placebo+G-CSF
Guangzhou Gloria Biosciences Co., Ltd.
Multiple Myeloma
08/26
12/26
NCT02639559: Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

Completed
2
50
US
BL-8040, Leukapheresis, Hematopoietic cell transplant
Washington University School of Medicine, BioLineRx, Ltd.
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease, Hodgkins Disease, Hodgkin's Disease, Multiple Myeloma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
04/18
04/23
NCT02907099: Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

Checkmark Data from trial in combination with BL-8040 in pancreatic cancer
Nov 2019 - Nov 2019: Data from trial in combination with BL-8040 in pancreatic cancer
Completed
2
20
US
CXCR4 Antagonist BL-8040, BKT140, BL-8040, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pharmacological Study
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
10/23
10/23
Chemo4METPANC, NCT04543071: Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Recruiting
2
10
US
Motixafortide, BL-8040, Cemiplimab, REGN2810, Gemcitabine, Gemzar, Nab paclitaxel, Abraxane
Gulam Manji, Regeneron Pharmaceuticals, BioLine Rx
Pancreatic Cancer, Adenocarcinoma of the Pancreas, Adenocarcinoma
06/28
08/28
MORPHEUS-EC, NCT03281369 / 2016-004529-17: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Active, not recruiting
1/2
410
Europe, US, RoW
5-Fluorouracil (5-FU), Leucovorin, Folinic acid, Oxaliplatin, Atezolizumab, Tecentriq, Cobimetinib, Cotellic, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Cisplatin, Tiragolumab, RO7092284
Hoffmann-La Roche, Halozyme Therapeutics, BioLineRx, Ltd.
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
09/25
09/25
MORPHEUS-PDAC, NCT03193190 / 2016-004126-42: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Hourglass Feb 2024 - Jun 2024 : Results from MORPHEUS-PDAC trial in 1L mPDAC
Checkmark In combination with BL-8040 for pancreatic ductal adenocarcinoma
Dec 2019 - Dec 2019: In combination with BL-8040 for pancreatic ductal adenocarcinoma
Completed
1/2
341
Europe, Japan, US, RoW
Nab-Paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Fluorouracil, Atezolizumab, Cobimetinib, PEGPH20, BL-8040, Selicrelumab, Bevacizumab, RO6874281, AB928, Tiragolumab, Tocilizumab
Hoffmann-La Roche
Pancreatic Adenocarcinoma
02/25
02/25
NCT05618301: Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

Active, not recruiting
1
10
US
Motixafortide, BL-8040, Natalizumab, Tysabri, Leukapheresis
Washington University School of Medicine, BioLineRx, Ltd., Biogen
Sickle Cell Disease
06/25
06/25
NCT06547112: A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization

Recruiting
1
20
US
Motixafortide, BL-8040, G-CSF
Washington University School of Medicine, BioLineRx, Ltd., Arvrmid Pharma
Multiple Myeloma
01/26
01/26
NCT06442761: SCD Stem Cell Mobilization and Apheresis Using Motixafortide

Recruiting
1
15
US
Motixafortide, APHEXDA™
St. Jude Children's Research Hospital, BioLineRx, Ltd.
Sickle Cell Disease
01/26
07/26
Omisirge (omidubicel) / Ayrmid
GC P#05.01.020, NCT02730299 / 2016-000704-28: Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

Completed
3
125
Europe, US, RoW
NiCord® (omidubicel), Cord Blood Unit
Gamida Cell ltd
Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Lymphoma, Acute Leukemia
04/21
02/25
NCT04260698: Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

Completed
3
36
US
omidubicel, NiCord
Gamida Cell ltd
Hematological Malignancies
05/25
05/25
NCT03173937: Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

Recruiting
1/2
37
US
Omidubicel (former CordIn), Miltenyi CliniMACS(R) CD34 Reagent System
National Heart, Lung, and Blood Institute (NHLBI)
Severe Aplastic Anemia, Hypo-Plastic MDS, Myelodysplastic Syndrome (MDS)
04/27
03/32
NCT06731504: HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT

Not yet recruiting
1
10
NA
Abatacept
Duke University
Hematologic Malignancy
12/27
07/28
NCT02039557 / 2015-004813-26: Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients

Completed
N/A
33
Europe, US, RoW
NiCord®/CordIn™ (omidubicel)
Gamida Cell ltd
Patients Transplanted With NiCord/CordIn (Omidubicel)
06/23
06/23
GDA-201 / Ayrmid
NCT05296525: Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL

Terminated
1/2
13
US
GDA-201, Nicotinamide (NAM) NK
Gamida Cell ltd
Non-Hodgkin Lymphoma
04/24
04/24
GDA-301 / Ayrmid
No trials found
GDA-401 / Ayrmid
No trials found
GDA-501 / Ayrmid
No trials found
GDA-601 / Ayrmid
No trials found

Download Options